全球癌症疫苗市場：趨勢、預測與競爭分析（~2030 年）

預計2030年，全球癌症疫苗市場規模將達到155億美元，2024年至2030年複合年成長率為10.5%。該市場的主要促進因素包括對更有效、侵入性更小的癌症治療的需求不斷成長、人們對癌症疫苗益處的認知不斷提高以及政府促進癌症疫苗接種的支持措施。全球癌症疫苗市場前景廣闊，醫院和政府供應管道充滿機會。

• 由於其在預防癌症發作方面的預防作用，預計預防市場在預測期內將出現最高成長。
• 在這個市場中，由於在醫院接受癌症診斷和治療的人數不斷增加，醫院在預測期內預計將出現高速成長。
• 由於癌症患者數量不斷增加以及該地區醫療保健系統的建立，預計北美地區在預測期內將出現最高的成長。

癌症疫苗市場新趨勢

癌症疫苗市場的新興趨勢正在塑造癌症治療和預防的未來。這些趨勢集中在技術進步、個人化醫療以及影響疫苗開發和採用的市場動態。

• mRNA 技術的進步：針對多種癌症的 mRNA 疫苗正在開發中，為個人化治療和標靶免疫反應提供了潛力，帶來創新和有效的癌症治療。
• 個人化癌症疫苗：針對個人獨特癌症特徵量身訂製的個人化癌症疫苗越來越受歡迎。這些疫苗旨在透過針對特定腫瘤抗原來刺激免疫系統，以提高療效並減少副作用，代表著向更客製化和更有效的癌症治療的轉變。
• 人工智慧的整合：人工智慧（AI）擴大融入癌症疫苗的開發中。人工智慧演算法用於識別潛在的癌症標靶、最佳化疫苗設計並分析臨床試驗資料，加快開發進程並提高疫苗療法的準確性。
• 增加對免疫腫瘤學的投資：對免疫腫瘤學的投資增加，其重點是開發利用人體免疫系統來對抗癌症的疫苗。這一趨勢是由突破性治療方法的潛力以及對癌症治療中免疫系統機制的日益了解所推動的。
• 全球合作和夥伴關係：生物技術公司、學術機構和研究機構之間日益加強的全球合作和夥伴關係正在促進癌症疫苗的開發。這些合作促進了知識、資源和技術的共用，從而推動疫苗研究的進步並加速創新。

mRNA 技術的進步、個人化癌症疫苗、人工智慧的整合、免疫腫瘤學投資的增加以及全球研究合作等新興全球趨勢正在重塑癌症疫苗市場。這些趨勢正在推動創新、提高精確度並改善治療結果，從而帶來更有效和個人化的癌症治療。

癌症疫苗市場的最新趨勢

癌症疫苗市場的最新趨勢反映了研究、技術和監管支援的重大進展。這些發展正在促進提高疫苗的功效、個人化和可及性。

• 基於 mRNA 的癌症疫苗的開發：基於 mRNA 的癌症疫苗的開發是一項重大進展。這些疫苗利用 mRNA 平台編碼癌症特異性抗原並引發有針對性的免疫反應。早期臨床試驗的成功以及 mRNA 技術在 COVID-19 疫苗中的應用正在加速該領域的進展。
• 新的治療性癌症疫苗的核准：新的治療性癌症疫苗的核准正在擴大治療選擇。最近監管部門核准了針對黑色素瘤和前列腺癌等疾病的疫苗，這為創新治療方法和更廣泛的臨床應用鋪平了道路。
• 臨床試驗擴大：癌症疫苗臨床試驗大幅擴大，參與國際合作試驗增加。這項擴展可以對疫苗的功效和安全性進行更全面的測試，並加速開發針對多種癌症的新的和改進的疫苗。
• 聯合治療的出現：癌症疫苗與查核點抑制劑和標靶治療治療等其他治療方法的聯合治療是一個顯著的發展。將疫苗與其他治療方法結合可以提高治療效果，並提供治療複雜癌症的新方法。
• 關注全球可及性和可負擔性：提高癌症疫苗全球可近性和可負擔性的努力正在取得進展。低收入和中等收入國家降低生產成本和增加疫苗供應的努力正在解決差異並加強全球癌症預防工作。

最近的趨勢，例如基於 mRNA 的疫苗的進展、新治療疫苗的核准、臨床試驗的擴大、聯合治療的出現以及對全球可及性的重視，正在對癌症疫苗市場產生重大影響。這些措施將促進創新、改善治療選擇並增加癌症治療的機會。

癌症疫苗市場的策略性成長機會

在技​​術、研究和全球醫療保健需求進步的推動下，癌症疫苗市場的策略性成長機會在各種應用中不斷出現。這些機會為擴大市場範圍和增強治療選擇指明了道路。

• 擴大個人化疫苗：擴大個人化癌症疫苗的開發代表著一個重大的成長機會。透過根據個別患者情況和腫瘤特徵量身定做疫苗，這種方法提供了更有效的治療和改善患者預後的潛力。
• mRNA 和 DNA 疫苗技術的進步：mRNA 和 DNA 疫苗技術的進步為開發標靶癌症治療方法提供創新平台，創造了成長機會。這些技術使得能夠製造特異性針對癌細胞的疫苗，從而提供新的治療可能性。
• 聯合治療的整合：癌症疫苗與免疫查核點抑制劑和標靶治療治療等其他治療方法的整合帶來了成長機會。聯合治療可以提高治療效果並針對多種癌症類型，改善患者的治療效果並擴大市場潛力。
• 關注全球市場滲透率：亞太和拉丁美洲等新興地區市場滲透率的提高是一個成長機會。透過滿足當地的醫療保健需求和增加疫苗的可及性，公司可以開拓新市場並加強其全球影響力。
• 投資研究合作：投資與學術機構和生技公司的研究合作和夥伴關係可提供成長機會。這些合作將加速尖端疫苗技術的開發，並加速新癌症治療的進展。

癌症疫苗市場的策略性成長機會包括個人化疫苗的擴張、mRNA和DNA技術的進步、聯合治療的整合、專注於全球市場滲透以及合作研究的投資。這些機會將促進創新、增強治療選擇並擴大癌症治療的市場範圍。

癌症疫苗市場推廣因素及挑戰

癌症疫苗市場受到各種市場促進因素和挑戰的影響，包括技術進步、監管因素和經濟考量。了解這些因素對於駕馭市場和推動成長至關重要。

推動癌症疫苗市場的因素包括：

1.技術進步：mRNA疫苗和DNA疫苗平台等技術創新使標靶和個人化癌症治療的開發成為可能，推動市場成長。這些創新將提高疫苗功效並擴大治療選擇。

2.增加研究投入：增加癌症疫苗研究的投入將支持新型有效疫苗的開發。來自政府機構、私人投資者和製藥公司的資金將加速研究並促進疫苗創新。

3. 意識和需求的提高：癌症預防和早期檢測意識的提高將推動對癌症疫苗的需求。大眾和專業人士對疫苗接種益處的認知將有助於增加市場採用和投資。

4. 監管支持和核准：創新癌症疫苗的監管支持和簡化的核准流程將促進其進入市場。快速核准和支持性法律規範使新治療方法能夠快速開發和上市。

5. 合作研究計畫：學術界、工業界和研究機構之間的合作研究舉措促進癌症疫苗開發的創新和進步。夥伴關係關係促進知識共用、資源分配和技術進步。

癌症疫苗市場面臨的挑戰包括：

1. 開發成本高：癌症疫苗研究和臨床試驗的開發成本高是一個問題。平衡成本、負擔能力和市場潛力對於新疫苗的成功商業化至關重要。

2. 監管和合規複雜性：應對複雜的監管要求和合規問題是一項挑戰。確保遵守不同的地區法規增加了疫苗開發和市場准入的複雜性。

3.市場進入和分配問題： 市場准入和分配挑戰：市場准入和分配挑戰，特別是在低收入和中等收入國家，影響癌症疫苗的供應和價格。解決這些問題對於擴大全球影響力和改善准入至關重要。

癌症疫苗市場的關鍵促進因素包括技術進步、研究投資增加、意識和需求不斷提高、監管支持和合作研究措施。主要挑戰包括高昂的開發成本、監管複雜性和市場進入問題。解決這些因素對於促進癌症疫苗市場的成長和創新至關重要。

癌症疫苗按市場

該研究按疫苗類型、技術、分銷管道和地區對全球癌症疫苗進行了預測。

國家癌症疫苗市場前景

癌症疫苗市場的最新發展是由技術創新、研究投資增加和癌症預防意識不斷增強所推動的。美國、中國、德國、印度和日本取得了重大進展，反映出他們致力於透過疫苗開發改善癌症治療和預防策略。

• 美國：在美國，隨著個人化和治療性疫苗開發的進展，癌症疫苗市場正在經歷顯著成長。最近的趨勢包括開發針對多種癌症（如黑色素瘤和肺癌）的基於 mRNA 的疫苗。 FDA 加快了幾種創新癌症疫苗的核准，支持更廣泛的臨床試驗，並促進更快地獲得新療法。
• 中國：中國正在癌症疫苗市場快速推進，加大對生物技術和臨床研究的投資。最近的趨勢包括多種國產癌症疫苗的臨床試驗，重點是肝細胞癌和其他常見癌症的治療方法。中國有利的法規環境和不斷提高的研究能力正在促進創新並加速新型癌症疫苗的開發。
• 德國：德國仍然是癌症疫苗開發的領導者，重點是精準醫療。最近的趨勢包括針對特定癌症生物標記的疫苗和個人化癌症免疫療法的開發。德國強大的研究基礎設施以及學術機構和工業界之間的合作正在推動創新並推動新癌症疫苗的臨床試驗。
• 印度：在印度，癌症疫苗市場正在不斷發展，重點是提供負擔得起且易於獲得的解決方案。最近的進展包括針對子宮頸癌和其他高負擔癌症推出具有成本效益的疫苗。印度不斷增強的研究能力和官民合作關係正在加強疫苗的開發和分配，並滿足該地區對預防性癌症疫苗的需求。
• 日本：日本在癌症疫苗研究方面正在取得突破，著重於先進技術與精準醫療的融合。最近的發展包括針對特定癌症的幾種創新候選疫苗的進展以及 mRNA 和基於載體的疫苗等尖端平台的使用。日本對研究和發展的承諾正在推動癌症疫苗治療的進步。

常問問題

Q.1 癌症疫苗的市場規模有多大？

A1. 到 2030 年，全球癌症疫苗市場預計將達到 155 億美元。

Q.2 癌症疫苗市場的成長預測如何？

A2. 2024年至2030年，全球癌症疫苗市場預計將以10.5%的複合年成長率成長。

Q.3 影響癌症疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要驅動力是對更有效、侵入性更小的癌症治療的需求不斷成長、人們對癌症疫苗益處的認知不斷提高以及政府對促進癌症疫苗接種的支持。

Q4.市場的主要細分市場是：

A4. 癌症疫苗市場前景廣闊，醫院和政府供應管道充滿機會。

Q5.市場的主要企業是：

A5. 主要癌症疫苗公司如下：

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Q6.未來最大的細分市場是什麼？

A6.預防癌症的預防性疫苗預計將在預測期內達到最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於癌症患者數量的增加和完善的醫療保健系統，預計北美在預測期內將出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，我們提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球癌症疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球癌症疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 全球癌症疫苗市場：依疫苗類型
  • 預防
  • 治療性的
• 全球癌症疫苗市場：依技術分類
  • 重組
  • 全細胞
  • 病毒載體
  • DNA癌症疫苗
• 全球癌症疫苗市場：按分銷管道分類
  • 醫院
  • 政府供應

第4章市場趨勢與預測分析：按地區分類，2018-2030

• 全球癌症疫苗市場：按地區
• 北美癌症疫苗市場
• 歐洲癌症疫苗市場
• 亞太地區癌症疫苗市場
• 其他地區癌症疫苗市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按疫苗類型
  • 依技術
  • 按分銷管道
  • 按地區
• 全球癌症疫苗市場新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球癌症疫苗市場產能
  • 全球癌症疫苗市場的併購和合資企業
  • 認證和許可

第7章主要企業概況

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Cancer Vaccine Trends and Forecast

The future of the global cancer vaccine market looks promising with opportunities in the hospital and government supplier channels. The global cancer vaccine market is expected to reach an estimated $15.5 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive cancer treatment, growing awareness of the benefits of cancer vaccines, and supportive government initiatives to promote cancer vaccination.

• Lucintel forecasts that preventive is expected to witness highest growth over the forecast period due to its ability to prevent cancer from developing in the first place.
• Within this market, hospital is expected to witness higher growth over the forecast period due to the increasing number of individuals seeking cancer diagnosis and treatment in hospitals.
• North America is expected to witness highest growth over the forecast period due to the rising number of cancer patients and presence of well-established healthcare system in the region.

Emerging Trends in the Cancer Vaccine Market

Emerging trends in the cancer vaccine market are shaping the future of cancer treatment and prevention. These trends highlight advancements in technology, personalized medicine, and market dynamics influencing vaccine development and adoption.

• Advancement of mRNA Technology: The use of mRNA technology in cancer vaccines is a major trend, driven by its success in COVID-19 vaccines. mRNA vaccines are being developed for various cancers, offering the potential for personalized treatment and targeted immune responses, leading to innovative and effective cancer therapies.
• Personalized Cancer Vaccines: Personalized cancer vaccines, tailored to an individual's unique cancer profile, are gaining traction. These vaccines aim to stimulate the immune system to target specific tumor antigens, improving efficacy and reducing side effects, which represents a shift towards more customized and effective cancer treatments.
• Integration of Artificial Intelligence: Artificial Intelligence (AI) is increasingly being integrated into cancer vaccine development. AI algorithms are used to identify potential cancer targets, optimize vaccine designs, and analyze clinical trial data, accelerating the development process and enhancing the precision of vaccine therapies.
• Increased Investment in Immuno-Oncology: There is a growing investment in immuno-oncology, focusing on developing vaccines that harness the body's immune system to fight cancer. This trend is driven by the potential for breakthrough therapies and the growing understanding of immune system mechanisms in cancer treatment.
• Global Collaborations and Partnerships: Increased global collaborations and partnerships between biotech companies, academic institutions, and research organizations are enhancing the development of cancer vaccines. These collaborations facilitate the sharing of knowledge, resources, and technologies, leading to accelerated progress and innovation in vaccine research.

Emerging trends such as the advancement of mRNA technology, personalized cancer vaccines, integration of AI, increased investment in immuno-oncology, and global collaborations are reshaping the cancer vaccine market. These trends drive innovation, enhance precision, and improve treatment outcomes, leading to more effective and personalized cancer therapies.

Recent Developments in the Cancer Vaccine Market

Recent developments in the cancer vaccine market reflect significant progress in research, technology, and regulatory support. These developments are driving advancements in vaccine efficacy, personalization, and accessibility.

• Development of mRNA-Based Cancer Vaccines: The development of mRNA-based cancer vaccines represents a major advancement. These vaccines leverage the mRNA platform to encode cancer-specific antigens, triggering targeted immune responses. Success in early trials and the application of mRNA technology from COVID-19 vaccines are accelerating progress in this area.
• Approval of New Therapeutic Vaccines: The approval of new therapeutic cancer vaccines has expanded treatment options. Recent approvals by regulatory agencies for vaccines targeting melanoma, prostate cancer, and other types are paving the way for innovative therapies and broader clinical use.
• Expansion of Clinical Trials: There has been a significant expansion in clinical trials for cancer vaccines, with increased participation in global studies. This expansion allows for more comprehensive testing of vaccine efficacy and safety, facilitating the development of new and improved vaccines for various cancers.
• Emergence of Combination Therapies: The use of combination therapies, integrating cancer vaccines with other treatments such as checkpoint inhibitors or targeted therapies, is a notable development. Combining vaccines with other modalities enhances treatment efficacy and offers new approaches to managing complex cancers.
• Focus on Global Access and Affordability: Efforts to improve global access and affordability of cancer vaccines are gaining momentum. Initiatives to reduce production costs and increase vaccine availability in low- and middle-income countries are addressing disparities and enhancing global cancer prevention efforts.

Recent developments such as the advancement of mRNA-based vaccines, approval of new therapeutic vaccines, expansion of clinical trials, emergence of combination therapies, and focus on global access are significantly impacting the cancer vaccine market. These developments drive innovation, improve treatment options, and enhance accessibility in cancer care.

Strategic Growth Opportunities for Cancer Vaccine Market

Strategic growth opportunities in the cancer vaccine market are emerging across various applications, driven by advancements in technology, research, and global healthcare needs. These opportunities present avenues for expanding market reach and enhancing therapeutic options.

• Expansion of Personalized Vaccines: Expanding the development of personalized cancer vaccines presents a significant growth opportunity. By tailoring vaccines to individual patient profiles and tumor characteristics, this approach offers the potential for more effective treatments and improved patient outcomes.
• Advancement in mRNA and DNA Vaccine Technologies: Advancements in mRNA and DNA vaccine technologies create growth opportunities by providing innovative platforms for developing targeted cancer therapies. These technologies enable the creation of vaccines that specifically target cancer cells, offering new treatment possibilities.
• Integration of Combination Therapies: Integrating cancer vaccines with other therapeutic modalities, such as immune checkpoint inhibitors or targeted therapies, offers a growth opportunity. Combination therapies can enhance treatment efficacy and address diverse cancer types, leading to improved patient outcomes and market potential.
• Focus on Global Market Penetration: Expanding market penetration in emerging regions, such as Asia-Pacific and Latin America, offers growth opportunities. By addressing local healthcare needs and increasing vaccine accessibility, companies can tap into new markets and enhance global reach.
• Investment in Collaborative Research: Investing in collaborative research and partnerships with academic institutions and biotechnology firms provides growth opportunities. These collaborations facilitate the development of cutting-edge vaccine technologies and accelerate the advancement of new cancer treatments.

Strategic growth opportunities in the cancer vaccine market include expansion of personalized vaccines, advancement in mRNA and DNA technologies, integration of combination therapies, focus on global market penetration, and investment in collaborative research. These opportunities drive innovation, enhance treatment options, and expand market reach in cancer care.

Cancer Vaccine Market Driver and Challenges

The cancer vaccine market is influenced by various drivers and challenges, including technological advancements, regulatory factors, and economic considerations. Understanding these factors is essential for navigating the market and fostering growth.

The factors responsible for driving the cancer vaccine market include:

1. Technological Advancements: Technological advancements, such as mRNA and DNA vaccine platforms, drive market growth by enabling the development of targeted and personalized cancer therapies. These innovations improve vaccine efficacy and expand treatment options.

2. Increased Investment in Research: Increased investment in cancer vaccine research supports the development of new and effective vaccines. Funding from government agencies, private investors, and pharmaceutical companies accelerates research and enhances vaccine innovation.

3. Growing Awareness and Demand: Growing awareness of cancer prevention and early detection drives demand for cancer vaccines. Public and professional recognition of the benefits of vaccination contributes to increased market adoption and investment.

4. Regulatory Support and Approvals: Regulatory support and streamlined approval processes for innovative cancer vaccines facilitate market entry. Accelerated approvals and supportive regulatory frameworks enable faster development and availability of new treatments.

5. Collaborative Research Initiatives: Collaborative research initiatives between academia, industry, and research organizations drive innovation and progress in cancer vaccine development. Partnerships enhance knowledge sharing, resource allocation, and technology advancement.

Challenges in the cancer vaccine market are:

1. High Development Costs: High development costs associated with cancer vaccine research and clinical trials pose a challenge. Balancing costs with affordability and market potential is crucial for the successful commercialization of new vaccines.

2. Regulatory and Compliance Complexities: Navigating complex regulatory requirements and compliance issues can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

3. Market Access and Distribution Issues: Market access and distribution challenges, particularly in low- and middle-income countries, impact the availability and affordability of cancer vaccines. Addressing these issues is essential for expanding global reach and improving access.

Major drivers of the cancer vaccine market include technological advancements, increased investment in research, growing awareness and demand, regulatory support, and collaborative research initiatives. Key challenges include high development costs, regulatory complexities, and market access issues. Addressing these factors is vital for fostering growth and innovation in the cancer vaccine market.

List of Cancer Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies cancer vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer vaccine companies profiled in this report include-

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Cancer Vaccine by Segment

The study includes a forecast for the global cancer vaccine by vaccine type, technology, distribution channel, and region.

Cancer Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

• Preventive
• Therapeutic

Cancer Vaccine Market by Technology [Analysis by Value from 2018 to 2030]:

• Recombinant
• Whole-Cell
• Viral Vector
• DNA Cancer Vaccines

Cancer Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospitals
• Government Suppliers

Cancer Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cancer Vaccine Market

Recent advancements in the cancer vaccine market are driven by technological innovations, increasing investment in research, and growing awareness of cancer prevention. Key developments are being observed in the United States, China, Germany, India, and Japan, reflecting each country's focus on improving cancer treatment and prevention strategies through vaccine development.

• United States: In the U.S., the cancer vaccine market is experiencing significant growth with ongoing advancements in personalized and therapeutic vaccines. Recent developments include the progression of mRNA-based vaccines targeting various cancers, such as melanoma and lung cancer. The FDA has accelerated approvals for several innovative cancer vaccines, supporting broader clinical trials and facilitating faster access to novel treatments.
• China: China is rapidly advancing in the cancer vaccine market with increased investment in biotechnology and clinical research. Recent developments include the progress of several domestic cancer vaccines in clinical trials, focusing on therapies for hepatocellular carcinoma and other prevalent cancers. China's supportive regulatory environment and growing research capabilities are driving innovation and accelerating the development of new cancer vaccines.
• Germany: Germany continues to be a leader in cancer vaccine development with a strong emphasis on precision medicine. Recent advancements include the development of vaccines targeting specific cancer biomarkers and personalized cancer immunotherapies. Germany's robust research infrastructure and collaboration between academic institutions and industry are fostering innovation and advancing clinical trials for novel cancer vaccines.
• India: In India, the cancer vaccine market is evolving with a focus on affordable and accessible solutions. Recent developments include the introduction of cost-effective vaccines for cervical cancer and other high-burden cancers. India's growing research capabilities and public-private partnerships are enhancing vaccine development and distribution, addressing the need for preventive cancer vaccines in the region.
• Japan: Japan is making strides in cancer vaccine research with a focus on integrating advanced technologies and precision medicine. Recent developments include the progress of several innovative vaccine candidates targeting specific cancers and the use of cutting-edge platforms like mRNA and vector-based vaccines. Japan's commitment to research and development is driving advancements in cancer vaccine therapies.

Features of the Global Cancer Vaccine Market

Market Size Estimates: Cancer vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer vaccine market size by vaccine type, technology, distribution channel, and region in terms of value ($B).

Regional Analysis: Cancer vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, technologies, distribution channels, and regions for the cancer vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the cancer vaccine market size?

Answer: The global cancer vaccine market is expected to reach an estimated $15.5 billion by 2030.

Q.2 What is the growth forecast for cancer vaccine market?

Answer: The global cancer vaccine market is expected to grow with a CAGR of 10.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive cancer treatment, growing awareness of the benefits of cancer vaccines, and supportive government initiatives to promote cancer vaccination.

Q4. What are the major segments for cancer vaccine market?

Answer: The future of the cancer vaccine market looks promising with opportunities in the hospital and government supplier channels.

Q5. Who are the key cancer vaccine market companies?

Answer: Some of the key cancer vaccine companies are as follows:

• Merck
• GSK
• Dendreon Pharmaceuticals
• Dynavax Technologies
• Ferring
• Amgen
• Moderna
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb

Q6. Which cancer vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that preventive is expected to witness highest growth over the forecast period due to its ability to prevent cancer from developing in the first place.

Q7. In cancer vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the rising number of cancer patients and presence of well-established healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer vaccine market by vaccine type (preventive and therapeutic), technology (recombinant, whole-cell, viral vector, and DNA cancer vaccines), distribution channel (hospitals and government suppliers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Cancer Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Cancer Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Cancer Vaccine Market by Vaccine Type
  • 3.3.1: Preventive
  • 3.3.2: Therapeutic
• 3.4: Global Cancer Vaccine Market by Technology
  • 3.4.1: Recombinant
  • 3.4.2: Whole-Cell
  • 3.4.3: Viral Vector
  • 3.4.4: DNA Cancer Vaccines
• 3.5: Global Cancer Vaccine Market by Distribution Channel
  • 3.5.1: Hospitals
  • 3.5.2: Government Suppliers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Cancer Vaccine Market by Region
• 4.2: North American Cancer Vaccine Market
  • 4.2.1: North American Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.2.2: North American Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.3: European Cancer Vaccine Market
  • 4.3.1: European Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.3.2: European Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.4: APAC Cancer Vaccine Market
  • 4.4.1: APAC Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.4.2: APAC Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers
• 4.5: ROW Cancer Vaccine Market
  • 4.5.1: ROW Cancer Vaccine Market by Vaccine Type: Preventive and Therapeutic
  • 4.5.2: ROW Cancer Vaccine Market by Distribution Channel: Hospitals and Government Suppliers

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cancer Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Cancer Vaccine Market by Technology
  • 6.1.3: Growth Opportunities for the Global Cancer Vaccine Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Cancer Vaccine Market by Region
• 6.2: Emerging Trends in the Global Cancer Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cancer Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: GSK
• 7.3: Dendreon Pharmaceuticals
• 7.4: Dynavax Technologies
• 7.5: Ferring
• 7.6: Amgen
• 7.7: Moderna
• 7.8: Sanofi
• 7.9: AstraZeneca
• 7.10: Bristol-Myers Squibb